User login

Bill To Lower Biologics Exclusivity Period Characterized As Unrelated To TPP

June 28, 2016 at 2:57 PM
A bipartisan bill to lower the exclusivity period for biologic drugs in the United States from 12 to seven years is being characterized as an attempt to cut costs on life-saving medicines, with supporters and detractors of the legislation refuting any connection to the ongoing fight over the period of exclusivity for biologic drugs required by the Trans-Pacific Partnership. Introduced on June 23 in the Senate by Finance Committee member Sherrod Brown (D-OH) and Sen. John McCain (R-AZ), and in...

Not a subscriber? You can request 30 days free access to exclusive, behind-the-scenes reporting on trade policy in the Biden era.